A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 144
- Registration Number
- NCT06004336
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Paranteral Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Randomized Controlled Study
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06004063
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Prophylactic Lymphovenous Bypass Procedure Following Inguinal Lymphadenectomy: a Prospective Observational Study
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05992909
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05985954
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05977998
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05967182
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05961696
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05961709
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Data Collection Protocol for Patients With Von Hippel Lindau Disease
Recruiting
- Conditions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 125
- Registration Number
- NCT05955014
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Reminder Messages for Lung Cancer Screening
Recruiting
- Conditions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT05952778
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath